Blog

Antibody-drug conjugates (ADCs) benefit from an elegant design. When functioning to their full potential, they entrust an antibody to guide a therapeutic payload directly to tumor cells, while avoiding unwanted effects on healthy tissue. This combination of...

Skin sensitization is defined as an allergic response triggered by a substance that induces an overreaction of the immune system, and it is a crucial concern for pharmaceutical and medical device developers. Rigorous testing for skin sensitization is an essential part...

Over the past decade, oligonucleotides have moved from a theoretical concept to a clinical mainstay, revolutionizing the rules of targeted therapy. By harnessing short, chemically synthesized strands of DNA or RNA, these molecules act as precision editors of gene...

Peptide therapeutics are among the most promising (and commercially successful) areas of drug development today Their high target specificity, favorable efficacy profiles, and manageable dosing regimens make them well suited for precision medicine approaches. Advances...

The transition from discovery research to clinical development represents a critical pivot point in drug manufacturing. To successfully advance a candidate, developers must execute a series of robust, comprehensive IND-enabling studies that satisfy regulatory...

The transition from research to clinical development represents a critical point in drug development. The IND (Investigational New Drug) application is often mischaracterized as a milestone to be cleared, but U.S FDA views it as a tool to protect patients and a legal...

Transitioning to the first IND clinical trial is fraught with many operational and scientific risks. While the regulatory submission process focuses on safety and justification, the execution phase shifts the burden toward meticulous laboratory performance. Often, a...

The transition from preclinical research to clinical investigation remains one of the most demanding phases in pharmaceutical development. While IND submission is often viewed as the finish line for early-stage development, regulatory authorities characterize it as...

One of the defining challenges in oligonucleotide therapeutics has not been ensuring their ability to modulate genes, but rather how to deliver their effects precisely where they are needed. Following the success of GalNAc conjugates in liver targeting, the field has...

Oncolytic viruses have emerged as a promising class of cancer therapeutics that combine direct tumor destruction with immune system activation. Unlike traditional oncology treatments, these engineered viruses are designed to selectively infect and replicate within...

Alzheimer’s disease (AD) is increasingly understood not only as a clinical syndrome, but as a biological disease process that begins years before memory loss or other cognitive symptoms become apparent. Because amyloid beta (Aβ) deposition, tau pathology,...

In the early stages of drug research, the ability to predict how a human body will process a chemical is essential for preventing failure in late-stage trials. This predictive ability is primarily driven by in vitro ADME testing, a suite of assays designed to evaluate...